ImmunityBio, Inc. (IBRX) Tops Q2 EPS by 1c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $26.43 million versus the consensus estimate of $21.49 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Active options: TSLA NVDA AMZN GOOGL AAPL SPCX MSFT NFLX INTC
• Incyte (INCY) PT Raised to $105 at Truist Securities